Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TiGenix

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

Brexit Means Brexit

The differential destinations of post-Brexit pharma

Sanofi reception

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Cemiplimab could be the first PD-1-targeting drug approved for CSCC

- PMLiVE

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

- PMLiVE

AZ finally gets EU nod for Veltassa rival Lokelma

And expects a US FDA verdict for the hyperkalaemia treatment later this year

- PMLiVE

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Will launch Herzuma in seven European countries including the UK and Germany

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Roche Basel Switzerland

Roche wins CHMP backing for Hemlibra

Haemophilia A treatment on course for European approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links